Compare TransMedics Group Inc (TMDX) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Workday Inc — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Workday Inc trades at $186.59 (market cap $45.26B). The key difference: Workday Inc is far larger — about 16.5× TransMedics Group Inc's market cap, and Workday Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Workday Inc for 38 Days on average.
| TMDX | WDAY | |
|---|---|---|
Market Cap | $2.74B | $45.26B |
Volume | 949,331 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $150.42 | $245.67 |
52-Week Low | $61.99 | $112.55 |
Typical Hold Time | 24 Days | 38 Days |
Enterprise Value | $3.13B | $45.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Workday (WDAY) trades at $187.81, up 1.93% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.75 exceeding the $2.61 forecast. Revenue growth is robust, projected to reach $10.2B in 2026, and the company maintains a high gross profit margin of 75.8%. Recent strategic moves include expansion into the UAE and AI product launches, though layoffs signal operational realignment.
The outlook for WDAY is positive, driven by AI integration and solid financials, but risks include competitive pressures and execution challenges. Analyst consensus is a Buy with a $202.92 price target, suggesting upside potential. Investors should weigh strong profitability against valuation multiples that remain elevated compared to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
